A randomized phase II trial of interleukin-2/interferon-α plus bevacizumab versus interleukin-2/interferon-α in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1
| Autor: | Niels Viggo Jensen, Line Brøndum, Torben Smidt-Hansen, Poul F. Geertsen, Frede Donskov |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Interleukin 2 Cancer Research medicine.medical_specialty Bevacizumab business.industry medicine.medical_treatment Cancer Immunotherapy medicine.disease 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma 030220 oncology & carcinogenesis Interferon α Internal medicine medicine business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:4563-4563 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.4563 |
| Popis: | 4563Background: The potential benefit of combining the antiangiogenic agent bevacizumab (BEV) with Interleukin-2/Interferon-alpha (IL2/IFN) immunotherapy is unknown. This randomized, open-label, ph... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|